Key keywords: TrumpRx expansion, Mark Cuban Cost Plus Drug Company, White House prescription drug policy, affordable prescription drugs, US healthcare reform, out-of-pocket medication costs, generic drug access, pharmacy benefit manager reform The White House is set to officially announce a landmark expansion of the TrumpRx prescription drug affordability program in partnership with entrepreneur Mark Cuban’s Cost Plus Drug Company, according to senior administration officials who shared exclusive details ahead of the formal public rollout scheduled for later this week. First launched as a limited pilot program in early 2024 to lower medication costs for uninsured and underinsured Americans, the expanded TrumpRx program will leverage Cost Plus’s proven transparent pricing model and streamlined supply chain infrastructure to deliver discounted prescription drugs to more than 150 million U.S. residents, including Medicare and Medicaid beneficiaries, employer-sponsored insurance plan members, and consumers with no formal health coverage. Under the terms of the cross-sector partnership, more than 1,200 FDA-approved generic medications for common chronic conditions including type 2 diabetes, hypertension, asthma, high cholesterol, and autoimmune disorders will be available through the TrumpRx platform at prices 40% to 80% lower than average U.S. retail pharmacy prices, with zero hidden markup from pharmacy benefit managers (PBMs) that independent policy analysts have long blamed for inflating national prescription drug costs by as much as 50% annually. Mark Cuban, who founded Cost Plus Drug Company in 2022 with the explicit mission of eliminating excessive price gouging in the pharmaceutical supply chain, will join President Trump on stage at the White House announcement event to outline shared goals for the program. Administration officials note that the expanded program will eliminate burdensome prior authorization requirements for 90% of medications covered under the TrumpRx formulary, allowing patients to access their prescriptions in as little as two business days via free nationwide home delivery, or pick them up at more than 18,000 participating retail pharmacies across all 50 U.S. states and Puerto Rico. For Medicare beneficiaries, all medication purchases made through the TrumpRx platform will apply directly toward the annual Part D out-of-pocket cap, further reducing cost burdens for elderly and disabled patients who often spend thousands of dollars per year on life-sustaining medications. Early economic analysis from the U.S. Department of Health and Human Services estimates that the expanded TrumpRx program will save American households an average of $1,350 per year on prescription drug costs, while reducing overall U.S. healthcare spending by an estimated $72 billion over the next five years. The program is set to launch a national pilot on October 1, 2024, with full nationwide rollout completed by January 15, 2025. President Trump is also expected to announce additional executive actions during the event to cap insulin costs at $35 per month for all consumers, regardless of insurance status, as part of the broader TrumpRx expansion package.